A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
Status:
Completed
Trial end date:
2016-06-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor
antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Menlo Therapeutics Inc. Vyne Therapeutics Inc.
Treatments:
Neurokinin A Neurokinin-1 Receptor Antagonists Serlopitant Substance P